Cannabinoid pathways may offer targets for kidney disease as CKD affects 850 million people
Approximately 850 million people globally (9.1% of the world's population) have chronic kidney disease (CKD). The number of affected individuals has grown steadily during the past 20 years and is on track to continue rising. Existing drugs, such as RAAS inhibitors and angiotensin receptor blockers,
<p>Approximately 850 million people globally (9.1% of the world's population) have chronic kidney disease (CKD). The number of affected individuals has grown steadily during the past 20 years and is on track to continue rising. Existing drugs, such as RAAS inhibitors and angiotensin receptor blockers, </p>